ANI Pharmaceuticals (ANIP) FY2018 results: revenue $202 million, up 14.0% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $202 million for fiscal 2018, the year ended 31 December 2018, up 14.0% on the year before. Net income was $15 million, and diluted earnings per share $1.30. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2019.
Revenue
$202 million
+14.0% on the year
FY2011FY2018
Operating margin
17.5%
16.0% a year earlier
FY2011FY2018
Net income
$15 million
FY2011FY2018
Diluted EPS
$1.30
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
202
177
129
+14.0%
Cost of revenue
73.0
79.0
48.8
-7.6%
Gross profit
129
97.8
79.8
+31.4%
Gross margin
63.8%
55.3%
62.1%
Research and development
15.4
9.1
2.9
+69.7%
Selling, general and administrative
44.1
31.6
27.8
+39.5%
Operating income
35.4
28.3
20.1
+24.8%
Operating margin
17.5%
16.0%
15.6%
Interest expense
14.9
11.3
11.3
+31.7%
Pre-tax income
20.1
16.3
8.7
+22.6%
Income tax
4.6
17.4
4.7
-73.8%
Effective tax rate
22.7%
106.6%
54.7%
Net income
15.5
-1.1
3.9
Net margin
7.7%
-0.6%
3.1%
Diluted EPS
$1.30
-$0.09
$0.34
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
67.1
39.4
27.5
+70.2%
Capital expenditure
5.7
10.4
4.6
-44.6%
Free cash flow
61.3
29.1
22.9
+111.1%
Free cash flow margin
30.4%
16.4%
17.8%
Cash from investing
-27.4
-108
-149
Cash from financing
-27.8
72.4
-0.7
Depreciation and amortisation
33.7
27.9
22.3
+20.8%
Share-based compensation
6.8
6.1
6.1
+11.4%
Buybacks
0.0
0.0
2.5
Diluted shares, weighted
12m
12m
12m
+1.9%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
197
175
170
+12.9%
Debt
183
202
121
-9.2%
Other liabilities
50.3
35.9
32.6
+40.3%
Total liabilities and equity
431
412
323
+4.5%
Fixed assets
38.1
20.4
11.0
+86.7%
Goodwill
3.6
1.8
1.8
+94.8%
Intangible assets
202
230
176
-12.3%
Cash and equivalents
43.0
31.1
27.4
+38.1%
Receivables
64.8
58.8
45.9
+10.3%
Inventory
40.5
37.7
26.2
+7.4%
Other assets
39.0
32.4
34.8
+20.1%
Total assets
431
412
323
+4.5%
10-K for the year ended 31 December 2018, filed 27 February 2019: the filing.